Regulus Therapeutics Inc. (RGLS)

Regulus Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	115	26	23	27	53	19
Market Cap Growth	1221.04%	12.20%	-15.86%	-48.14%	183.87%	128.72%
Enterprise Value	19	4	-10	-26	26	-1
PE Ratio	-	-0.86	-0.81	-0.99	-3.36	-1.00
PS Ratio	-	-	-	-	5.28	2.73
PB Ratio	1.07	1.22	0.69	0.50	2.03	0.93
P/FCF Ratio	-6.68	-0.95	-0.89	-1.12	-4.22	-0.94
P/OCF Ratio	-6.88	-0.97	-0.90	-1.14	-4.22	-0.94
EV/Sales Ratio	-	-	-	-	2.64	-0.13
EV/EBITDA Ratio	-3.02	-0.15	0.36	0.98	-1.96	0.06
EV/EBIT Ratio	-2.99	-0.15	0.36	0.96	-1.90	0.05
EV/FCF Ratio	-3.27	-0.16	0.38	1.06	-2.11	0.04
Debt / Equity Ratio	0.01	0.11	0.19	0.13	0.18	0.73
Debt / EBITDA Ratio	-0.05	-0.08	-0.23	-0.27	-0.35	-0.94
Debt / FCF Ratio	-0.05	-0.09	-0.24	-0.29	-0.37	-0.74
Quick Ratio	17.18	2.80	3.36	11.56	2.73	1.63
Current Ratio	17.85	3.31	3.78	12.48	3.17	1.87
Asset Turnover	0	0	0	0	0.31	0.25
Interest Coverage	-61.73	-48.73	-40.17	-31.52	-7.70	-7.72
Return on Equity (ROE)	-65.70%	-109.20%	-68.80%	-75.20%	-109.90%	-401.00%
Return on Assets (ROA)	-55.40%	-80.60%	-52.90%	-55.40%	-48.50%	-68.20%
Return on Capital (ROIC)	-29.88%	-131.95%	-71.36%	-44.83%	-46.14%	-48.59%
Earnings Yield	-27.22%	-116.04%	-122.76%	-101.41%	-29.75%	-99.82%
FCF Yield	-24.50%	-105.77%	-112.21%	-88.91%	-23.71%	-105.90%
Buyback Yield / Dilution	-70.66%	-24.25%	-78.07%	-145.01%	-102.65%	-97.97%
Total Shareholder Return	-70.66%	-24.25%	-78.07%	-145.01%	-102.65%	-97.97%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).